---
document_datetime: 2025-12-22 15:19:28
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/osvyrti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: osvyrti-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9243836
conversion_datetime: 2026-01-03 12:27:08.138035
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Osvyrti

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | This was an application for a group of | 17/12/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000302844   | variations.   | Labelling and PL   |
|---------------------|---------------|--------------------|

<div style=\"page-break-after: always\"></div>

| glucocorticoid therapy and severe renal impairment (Glomerular filtration rate GFR &lt; 30 mL/min)\" in place of \"In Renal impairment section it is given that 'No data is available in patients with long-term systemic glucocorticoid therapy and severe renal impairment Glomerular filtration rate (GFR &lt; 30 mL/min). In section 5.1 in one multicentre, randomised, double-blind, placebo-controlled, parallel-group study conducted in 24 paediatric patients with glucocorticoid-induced osteoporosis, aged 5 to 17 years, evaluating change from baseline in lumbar spine BMD Z-score, safety and effectiveness were not established hence denosumab should not be used for this indication. In section 5.1 and 5.2 paediatric population \"phase 3\" replaced with \"phase III\"     C.I.2.a To amend SmPC section 4.4, following the outcome of a PSUSA assessment for the reference product by adding \"Treatment discontinuation Following denosumab discontinuation, decrease in bone mineral density (BMD) is expected (see section 5.1), leading to an increased risk for fractures. Thus, monitoring of BMD is recommended, and alternative treatment should be considered according to clinical guidelines.\"    C.I.2.a To amend SmPC section 4.8 to include the risk of Osteonecrosis of jaw.  In addition, the MAH has taken the opportunity to update Annex   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IIIA, on blister content, 5. other Section, and to harmonise with the reference SmPC and the package leaflet by adding the needle image in line with the reference product.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|